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Abstract
Background: Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) have emerged in high-HIV-
prevalence settings, which generally lack laboratory infrastructure for diagnosing TB drug resistance. Even where available,
inherent delays with current drug-susceptibility testing (DST) methods result in clinical deterioration and ongoing
transmission of MDR and XDR-TB. Identifying clinical predictors of drug resistance may aid in risk stratification for earlier
treatment and infection control.
Methods: We performed a retrospective case-control study of patients with MDR (cases), XDR (cases) and drug-susceptible
(controls) TB in a high-HIV-prevalence setting in South Africa to identify clinical and demographic risk factors for drug-
resistant TB. Controls were selected in a 1:1:1 ratio and were not matched. We calculated odds ratios (OR) and performed
multivariate logistic regression to identify independent predictors.
Results: We enrolled 116, 123 and 139 patients with drug-susceptible, MDR, and XDR-TB. More than 85% in all three patient
groups were HIV-infected. In multivariate analysis, MDR and XDR-TB were each strongly associated with history of TB
treatment failure (adjusted OR 51.7 [CI 6.6-403.7] and 51.5 [CI 6.4–414.0], respectively) and hospitalization more than 14 days
(aOR 3.8 [CI 1.1–13.3] and 6.1 [CI 1.8–21.0], respectively). Prior default from TB treatment was not a risk factor for MDR or
XDR-TB. HIV was a risk factor for XDR (aOR 8.2, CI 1.3–52.6), but not MDR-TB. Comparing XDR with MDR-TB patients, the only
significant risk factor for XDR-TB was HIV infection (aOR 5.3, CI 1.0–27.6).
Discussion: In this high-HIV-prevalence and drug-resistant TB setting, a history of prolonged hospitalization and previous TB
treatment failure were strong risk factors for both MDR and XDR-TB. Given high mortality observed among patients with HIV
and drug-resistant TB co-infection, previously treated and hospitalized patients should be considered for empiric second-
line TB therapy while awaiting confirmatory DST results in settings with a high-burden of MDR/XDR-TB.
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Introduction
Multidrug-resistant (MDR) and extensively drug-resistant
(XDR) tuberculosis (TB) continue to emerge in high HIV
prevalence settings, and their mortality in HIV co-infected patients
remains high [1–5]. Despite a rising global awareness of drug-
resistant TB, only 11% of the estimated cases of MDR TB were
notified to the World Health Organization in 2008 [6]. Most cases
likely go undetected due to insufficient laboratory infrastructure
for diagnosis; in the vast majority of clinical settings in the
developing world, culture and drug-susceptibility testing (DST) are
not available. Even where DST is available, routine use in all TB
suspects is often unfeasible due to limited sample processing
capacity of laboratories and cost. Furthermore, the most
commonly used culture and drug-susceptibility testing methodol-
ogies require six to eight weeks for results. In our studies of patients
with MDR and XDR TB and HIV-co-infection, the majority of
patients died within this time frame [4,7]. Delays in diagnosis of
drug-resistance also contribute to ongoing transmission [8]. Until
laboratory infrastructure can be strengthened or rapid diagnostics
made widely available, simple tools are needed to guide clinical
decision-making in high HIV and drug-resistant TB prevalence
settings.
Reliable assessment of a patient’s risk of drug-resistant TB can
enable targeting of DST where resources are limited. Further, it can
aid clinicians in identifying patients for early initiationof second line
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approach of early, aggressive management of drug-resistant TB has
been shown to contribute to good patient outcomes and higher cure
rates [9,10]. Risk stratifying patients based on easily and rapidly-
available clinical and/or laboratory data is commonly used in
developed and developing-world settings for medical decision-
making for a myriad of diseases [11–14]. However, few data have
been available from high HIV- and TB-prevalent, resource-poor
settings, where simple clinical tools to identify patients at high-risk
for drug-resistant TB are most needed.
While several studies have shown previous TB treatment to be a
risk factor for MDR TB [15,16], little is known about the relative
contribution of this and other risk factors in high HIV prevalence
settings. Drug-resistant TB risk factors are likely to differ in low-
resource, high HIV prevalence settings due to the increased risk of
transmission in congregate settings [17], more rapid progression to
active disease following infection [18], and higher mortality from
TB/HIV co-infection [4,19]. Thus, patients are less likely to
survive multiple prior courses of TB treatment and fit the classic
profile of a ‘‘chronic’’ TB case. Conversely, HIV/AIDS has been
associated with TB drug malabsorption [20], which may
contribute to higher rates of amplified drug resistance in this
setting. To date, there have been no studies of clinical or
epidemiologic risk factors for MDR or XDR TB in a high HIV
prevalence setting.
We undertook a case-control study in a community with a high
prevalence of HIV and drug-resistant tuberculosis in rural South
Africa to assess clinical predictors of multi-drug resistant and
extensively drug-resistant tuberculosis.
Methods
Ethics Statement
The study protocol was approved by the institutional review
boards of the Albert Einstein College of Medicine, Yale
University, and University of KwaZulu-Natal, and by the
KwaZulu-Natal Department of Health. The data used in this
study were collected as part of routine medical care in the hospital
clinical chart. As these were simply for clinical care, patients were
not asked to give informed consent at the time of these clinical
encounters. For the purposes of this retrospective study, the
requirement for informed consent was waived by the ethics
committees listed above, since all data used were previously
collected during the course of routine medical care and did not
pose any additional risks to the patients.
Setting
This study was conducted from June 2005 to January 2007 in
Tugela Ferry, South Africa, a rural community of approximately
200,000 Zulu people. The case notification rate of tuberculosis in
this community is over 1,100 per 100,000 population; MDR and
XDR TB incidence were 118 and 72 per 100,000, respectively, in
2007 [4]. Medical services are centered at Church of Scotland
Hospital (COSH), a 355-bed government district hospital in
Tugela Ferry, where a tuberculosis DOTS program has been in
place since 1993. During the time of this study, hospitalized
patients resided in congregate 35 to 40-bed wards. HIV
prevalence among women seeking antenatal care is estimated at
37%.
During the study period, culture and DST were available for
clinicians to order for any tuberculosis suspect, and clinicians were
encouraged to obtain these tests for all tuberculosis suspects. This
practice differed from other district hospitals in South Africa, and
from that recommended by national policy, which recommended
restriction of culture and drug-susceptibility testing to TB patients
who were failing their current first-line regimen or who were re-
treatment cases [21].
Mycobacterial culture was performed at the provincial TB
reference laboratory using both liquid (BACTEC mycobacterial
growth indicator tube (MGIT)-960 system) and solid media
(Middlebrook 7H10), as previously described [7]. Drug suscepti-
bility testing was performed on all positive mycobacterial cultures
by the 1% proportional method on Middlebrook 7H10 agar for
isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin and
kanamycin. Pyrazinamide is not included in the standard DST
panel, even though it is included in the standard first-line TB
treatment regimen.
Study population
We selected all patients with MDR and XDR TB diagnosed in
outpatient clinics or inpatient wards at COSH for whom complete
medical records were available for inclusion as cases in the study.
A control group of patients with drug-susceptible (DS) TB was
selected to achieve a 1:1:1 ratio of DS: MDR: XDR TB through
review of consecutive patients listed in the TB DOTS office
register diagnosed during the same period as cases. In order to
fully examine potential risk factors for drug-resistant tuberculosis,
patients were not matched by any demographic or clinical
variables.
Data Collection
We collected data from hospital medical records, TB DOTS
clinic records, and HIV clinic records. Variables of interest
included age, sex, HIV status, CD4 cell counts, antiretroviral
therapy (ART) use, extrapulmonary TB, presenting vital signs and
laboratory parameters, TB treatment history, and hospitalization
at COSH (for any reason) history.
Statistical Analyses
We compared clinical and demographicvariablesofpatients with
DS, MDR and XDR TB by Fisher’s exact test for categorical
variables and the Student’s t-test or Mann-Whitney U test for
continuous variables as guided by normality of the data. All three
groups were compared against each other (i.e. the MDR TB group
and XDR TB group were separately compared against the DS TB
group and compared against one another in two-way comparisons).
We calculated odds ratios (OR) and adjusted odds ratios (aOR)
using bivariate and multivariable logistic regression to assess
independent predictors of MDR TB or XDR TB compared with
DS TB controls, as well as XDR TB compared with MDR TB. A
cutoff criteria of p-value ,0.2 on bivariate analysis was used to
select variables for inclusion in the multivariate models comparing
MDR TB and XDR TB with DS TB (models 1 and 2
respectively). We performed an Allen-Cady modified, backward
selection procedure with gender and age included by default in all
models [22]. A cutoff criteria of p-value ,0.2 was utilized for
termination of variable elimination during backward selection. A
third model comparing XDR with MDR TB was constructed
using the same variables included in models 1 and 2 for ease of
comparison. All tests for significance were two-sided with a p-value
,0.05 considered significant. Bivariate and multivariable analyses
were performed using Stata (version 10.0).
Results
Demographic and Clinical Characteristics
Medical records were reviewed for 116, 123 and 139 patients
with DS, MDR and XDR TB, respectively, diagnosed between
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a mean of 2.9 drugs (SD 0.6); XDR TB patients were resistant to a
mean of 5.3 drugs (SD 0.8). The most common drug resistance
pattern for MDR TB isolates was resistance to isoniazid,
rifampicin, and streptomycin (80/123, 65%); the majority of
XDR TB isolates were resistant to all six drugs tested: isoniazid,
rifampicin, streptomycin, ethambutol, ciprofloxacin and kanamy-
cin (77/139, 55%). There were no differences in the median age of
patients in all three groups (Table 1). Female sex was more
common among XDR TB patients compared to DS and MDR
TB patients (p=0.03 and p=0.04, respectively). Approximately
one quarter of all patients were diagnosed with extrapulmonary
TB in addition to pulmonary TB. The most common form of
extrapulmonary TB was pericardial (41% of extrapulmonary
cases), followed by lymph node (24%) and pleural (15%).
The majority of patients with MDR (75%) and XDR TB (69%)
had been previously treated for drug-susceptible tuberculosis,
whereas only 27% of patients with DS tuberculosis had been
treated previously (p,0.0001 and p,0.0001, respectively;
Table 1). No patients had undergone prior treatment with
second-line drugs. Most previously treated patients in all three
groups had been treated within the previous year. Among
previously treated patients, most DS TB patients had been cured
(73%), while most MDR and XDR TB patients had failed
treatment (61% and 76%; p,0.0005 and p,0.0001, respectively).
Patients with MDR or XDR TB were more likely to have been
previously hospitalized compared to DS TB controls (p,0.0001
and p,0.0001, respectively; Table 1). Among patients that had
been hospitalized in the past year, patients with MDR and XDR
TB were hospitalized for more days (median 17 and 18 days,
respectively) than those with DS tuberculosis (11 days; p=0.04
and p=0.02, respectively).
Patients with XDR TB had a higher prevalence of HIV (98%)
than those with MDR TB (92%; p=0.06) or DS TB (87%;
p,0.01). There were no significant differences in median CD4 cell
count among the drug resistance groups, though there was a trend
towards lower CD4 cell counts among patients with MDR or
XDR TB. Among HIV-infected patients, those with MDR and
Table 1. Characteristics of patients with drug susceptible, multidrug-resistant and extensively drug-resistant tuberculosis.
DS MDR XDR MDR vs DS XDR vs DS
N 116 123 139 OR CI OR CI
Age, median (IQR) 35 (29–43) 34 (29–43) 34 (29–42) p=0.75 p=1.00
Female, n (%) 49 (42) 53 (43) 78 (56) 1.04 (0.62–1.73) 1.75 (1.06–2.88)*
Extrapulmonary, n (%) 26 (22) 34 (28) 41 (30) 1.32 (0.73–2.38) 1.45 (0.82–2.56)
Previous TB Treatment
Past year, n (%) 18 (16) 73 (59) 82 (59) 7.94 (4.28–14.75)* 7.83 (4.27–14.35)*
Ever, n (%) 31 (27) 92 (75) 96 (69) 8.13 (4.56–14.51)* 6.12 (3.54–10.57)*
Previous treatment status known, n (%) 26 (84) 70 (76) 78 (81)
Previous treatment status: cure, n (%) + 19 (73) 17 (24) 15 (19) 0.82 (0.40–1.67) 0.62 (0.30–1.28)
Previous treatment status: default, n (%) + 6 (23) 10 (14) 4 (5) 1.62 (0.57–4.62) 0.54 (0.15–1.97)
Previous treatment status: failure, n (%) + 1 (4) 43 (61) 59 (76) 61.81 (8.34–458.13)* 84.81 (11.51–624.80)*
Previous Hospitalization
Past year, n (%) 13 (11) 56 (46) 73 (53) 6.62 (3.36–13.04)* 8.76 (4.50–17.06)*
Ever, n (%) 23 (20) 69 (56) 83 (60) 5.17 (2.90–9.22)* 5.99 (3.39–10.58)*
Hospitalized .14 days, past year, n (%) 4 (3) 32 (26) 43 (31) 9.85 (3.36–28.87)* 12.5 (4.34–36.21)*
Days Hospitalized, past year u
median (range) 11 (4–36) 17 (6–109) 18 (3–105) 1.12 (1.07–1.17)* 1.14 (1.08–1.19)*
Weight, median (IQR) (kg) 52 (46–57) 48 (45–58) 50 (45–56) p=0.32 p=0.15*
Hemoglobin, median (IQR) (g/dL) 9.4 (7.7–10.8) 9.8 (7.9–11.5) 9.0 (7.7–10.4) p=0.28 p=0.97
Albumin, median (IQR) (g/dL) 25.7 (20.8–31.5) 28.0 (7.85–11.45) 21.0 (18.7–25.7) p=0.56 p=0.26
HIV tested, n (%) 90 (78) 92 (75) 117 (85)
HIV positive, n (% tested) 78 (87) 85 (92) 115 (98) 1.87 (0.70–4.99) 8.85 (1.93–40.62)*
CD4 Count Available, n (%){ 30 (38) 43 (51) 39 (34)
Median (IQR)1 110.5 (41–223) 87 (27–222) 60 (26–164) p=0.56 p=0.09*
,200 cells/mm2 21 (70) 31 (72) 34 (87) 1.11 (0.40–3.09) 2.91 (0.86–9.88)*
ART Before TB Diagnosis, n (%){ 3 (4) 13 (15) 25 (22) 4.51 (1.23–16.50)* 6.94 (2.02–23.90)*
Median duration among treated, days 113 62 120 p=0.42 p=0.77
uDays hospitalized are considered among patients who were hospitalized.
{CD4 cell count available and ART received before TB diagnosis were calculated among the fraction of patients known to have HIV.
1CD4 cell count was included if it was drawn within 120 days of TB diagnosis.
*Indicates p-value of ,0.2 (candidate for multivariable model).
+Percents calculated from fraction of patients with known retreatment; referent group for ORs was all patients without this retreatment classification (e.g. referent for
‘retreatment without cure’ includes previously untreated patients and those wiith other retreatment class).
doi:10.1371/journal.pone.0015735.t001
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the time of their drug-resistant TB diagnosis (p=0.02 and
p,0.005, respectively).
Independent predictors of drug resistance
In multivariable analysis comparing MDR or XDR TB cases
with DS TB controls, MDR and XDR TB were strongly
associated with a history of TB treatment failure (MDR aOR
51.7 [CI 6.6–403.7]; XDR aOR 51.5 [CI 6.4–414.0]) and
hospitalization more than 14 days (MDR aOR 3.8 [CI 1.1–
13.3], XDR aOR 6.1 [CI 1.8–21.0]; table 2). HIV was an
independent risk factor for XDR TB (aOR 8.2, [CI 1.3–52.6]) but
not for MDR TB (aOR 1.4 [CI 0.5–4.0]). Antiretroviral therapy
and CD4 cell count were not included in the model due to
collinearity with HIV.
Comparing MDR TB with XDR TB patients in multivariable
analysis, the only significant risk factor for XDR TB was HIV
infection (aOR 5.3, CI 1.0–27.6).
Discussion
Recent global data have shown rising rates of drug-resistant TB
in sub-Saharan Africa, the region also suffering from the world’s
highest burden of HIV/AIDS [23]. This is the first study of clinical
predictors of MDR and XDR TB in a high HIV prevalence
setting and provides important insights into the clinical charac-
teristics of patients with drug-resistant TB. We found that three
readily available pieces of clinical data – hospitalization history,
TB treatment history and HIV status – were strong independent
predictors for MDR or XDR TB. Using these data, clinicians
practicing in high HIV prevalence settings may be able to cohort
high-risk inpatients to reduce transmission and target drug-
susceptibility testing where DST resources are limited. Addition-
ally, our findings support the need for strengthening hospital
infection control measures, including reducing the duration of
hospitalization in high HIV prevalence settings.
Prior tuberculosis treatment is a well-established risk factor for
drug-resistant tuberculosis [15]. Studies from Peru and Russia
reported prior treatment among nearly all cases of MDR and
XDR TB, with XDR patients having received more courses of
therapy than MDR patients [9,24]. In contrast, nearly 30% of
patients in our study had no previous treatment for tuberculosis,
and few had received more than one previous treatment regimen.
Moreover, there were no patients who had received previous
treatment with second-line TB drugs. A recent study of patients
being re-treated for TB at Edendale Hospital in KwaZulu-Natal
reported an association between treatment failure and any drug
resistance [16]; however, only 7% of re-treatment patients in that
study had a history of treatment failure. In our study, a history of
TB treatment failure was associated with a 50-fold increase in risk
of having MDR or XDR TB and was the most common re-
treatment status among patients with MDR and XDR TB.
Our study also identified hospitalization as an important risk
factor for MDR and XDR tuberculosis, with prolonged hospital-
ization associated with a 3- to 6-fold increase in risk, respectively.
This finding further supports nosocomial transmission as a likely
driver of the epidemic in this setting, consistent with previous
studies from our site [25,26]. A recent study suggested that MDR
TB patients treated with first line regimens were responsible for
the majority of TB transmission on a tuberculosis ward [17].
Delays in the diagnosis of drug resistance and large, congregate
TB wards, that are the norm in many high burden settings, remain
a perilous combination for transmission of drug-resistant TB.
There has been conflicting evidence about whether HIV is an
independent risk factor for primary or acquired drug-resistant
tuberculosis [27–32]. We found HIV was associated with a
markedly greater risk of XDR TB compared with either DS TB or
MDR TB. These findings support the notion that HIV-infected
patients may be over-represented earlier in epidemics of drug-
resistant TB, as immunocompromised individuals are often first to
develop clinical disease from recently circulating strains.
Though the numbers were small, an unexpected finding in our
study was a significantly higher rate of antiretroviral therapy
(ART) use among patients with MDR and XDR TB. This may be
explained by the higher rate of previous TB treatment among
MDR and XDR TB patients (75% and 69%, respectively) as all
TB patients are routinely tested for HIV in Tugela Ferry and
initiated on ART within the first few months of treatment.
Another possible explanation is that HIV patients receiving ART
may have been exposed to other undiagnosed cases of MDR or
XDR TB while attending clinic visits. A recent active TB case-
finding study at our site identified high rates of undiagnosed MDR
and XDR TB among patients attending the HIV clinic (NS Shah,
unpublished data). Further molecular epidemiology studies are
needed to better define transmission patterns in hospital, clinic,
and community settings in Tugela Ferry. Nonetheless, improved
efforts to actively screen for TB and strengthen infection control in
HIV care and treatment facilities are needed to avoid undermin-
ing gains achieved by ART roll-out programs [33,34].
Few studies have compared patients with MDR and XDR TB
to determine whether they differ in clinical or demographic
characteristics. A report from Estonia, a country with low HIV
prevalence, found that they shared common predictor variables in
comparison to drug-susceptible TB, though direct comparisons
were not made [35]. In the high HIV prevalence setting in the
current study, there were few relevant clinical differences between
patients upon diagnosis, suggesting that control efforts – such as
Table 2. Adjusted risk factors for MDR and XDR TB, comparing MDR and XDR to DS TB, then XDR to MDR TB.
MDR vs DS XDR vs DS XDR vs MDR
Adjusted OR (95% CI) Adjusted OR (95% CI) Adjusted OR (95% CI)
Hospital admission for .14 days in past year 3.8 (1.1–13.3) 6.1 (1.8–21.0) 1.3 (0.7–2.6)
HIV infected 1.4 (0.5–4.0) 8.2 (1.3–52.6) 5.3 (1.0–27.6)
Previously treated and cured 1.6 (0.7–3.7) 1.1 (0.4–2.6) 0.7 (0.3–1.7)
Previously treated and defaulted 2.5 (0.5–12.3) 1.3 (0.2–8.0) 0.5 (0.1–2.3)
Previously treated and failed treatment 51.7 (6.6–403.7) 51.5 (6.4–414.0) 0.9 (0.4–1.7)
All models are adjusted for Age and Sex (not statistically significant and not shown).
doi:10.1371/journal.pone.0015735.t002
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sures – would be effective against both the MDR and XDR TB
epidemics.
These data must be interpreted in the context of the study
design and setting. First, this was a hospital-based study and may
reflect severity of disease and risk factors for TB patients diagnosed
at a hospital or at hospital-based clinics. Second, the prevalence of
MDR and XDR TB is higher in Tugela Ferry than that reported
from other districts in South Africa. The contribution of various
risk factors – such as hospitalization – is likely closely related to the
prevalence of drug resistance in the hospital and community.
However, the more widespread use of culture and DST in Tugela
Ferry provides a more representative sample of the true MDR and
XDR TB epidemic. As other high HIV prevalence communities
undertake similarly representative surveys, as recently performed
in Khayelitsha, South Africa, high drug-resistant TB prevalence
rates, similar to ours, may be uncovered [36].
Third, because DST results from the first TB episode were not
available on most re-treatment patients in our study, it is not
possible to know whether previous TB treatment was a risk factor
due to acquisition of drug-resistance or exogenous infection (or re-
infection) with drug-resistant strains. However, our prior studies
have found exogenous re-infection with drug-resistant strains to be
an important mechanism in this setting [25]. Moreover, because
no patients had received second-line TB drugs, XDR TB among
patients who were previously treated clearly represents primary
transmission of drug resistance.
Lastly, we did not evaluate certain demographic and clinical
variables identified in other studies as risk factors for MDR or
XDR TB – such as homelessness, alcohol use, and imprisonment
[35,37,38] – due to the lack of rigorous documentation of these
data in medical records. While imprisonment and homeless rates
are low in this community, alcohol use may be an important
factor.
Although there has been renewed enthusiasm for the develop-
ment and roll-out of low-cost, rapid drug-susceptibility tests for
TB, the majority of patients in resource-limited settings do not
have access to these new tests or even conventional drug-
susceptibility testing, even in settings such as South Africa with a
relatively advanced laboratory infrastructure [39]. Delays in
diagnosis lead to clinical deterioration of patients and ongoing
drug-resistant TB transmission in the community or hospital; in a
high HIV prevalence setting, this can have disastrous consequenc-
es. In the absence of universal culture and drug-susceptibility
testing for all TB patients, our study provides an evidence base for
better identifying high-risk patients for targeted drug-susceptibility
testing, isolation, and empiric use of second-line TB drugs while
awaiting results.
Acknowledgments
We are grateful to the staff of the Church of Scotland Hospital, the
Umzinyathi district Department of Health, and the KwaZulu-Natal
provincial TB control program. We thank the Inkosi Albert Luthuli
Central Hospital/National Health and Laboratory Services for performing
all TB culture and drug-susceptibility testing for patients from Tugela
Ferry. This work would not have been possible without the medical
students, residents, research assistants, and data capturers who contributed
to data collection and data cleaning. We also thank Dr. Moonseong Heo
for his helpful comments in the analysis used in this study. Dr. Heo’s
statistical support was provided by the Center for AIDS Research (CFAR)
of Albert Einstein College of Medicine/Montefiore Medical Center.
Author Contributions
Conceived and designed the experiments: NRG NSS JRA. Performed the
experiments: NRG NSS DW JRA. Analyzed the data: NRG NSS DW
JRA. Contributed reagents/materials/analysis tools: NRG NSS APM.
Wrote the paper: NRG NSS JRA.
References
1. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, et al. (2009) Early
outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern
Africa. PLoS ONE 4: e7186.
2. Calver AD, Falmer AA, Murray M, Strauss OJ, Streicher EM, et al. (2010)
Emergence of increased resistance and extensively drug-resistant tuberculosis
despite treatment adherence, South Africa. Emerging Infect Dis 16: 264–271.
3. Hassim S, Shaw PA, Sangweni P, Malan L, Ntshani E, et al. (2010) Detection of
a substantial rate of multidrug-resistant tuberculosis in an HIV-infected
population in South Africa by active monitoring of sputum samples. Clin
Infect Dis 50: 1053–1059.
4. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, et al. (2010) HIV
coinfection in multidrug- and extensively drug-resistant tuberculosis results in
high early mortality. Am J Respir Crit Care Med 181: 80–86.
5. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, et al. (2010) Early
treatment outcomes and HIV status of patients with extensively drug-resistant
tuberculosis in South Africa: a retrospective cohort study. Lancet 375:
1798–1807.
6. World Health Organization (2009) Global Tuberculosis Control: A short update
to the 2009 report. Geneva, Switzerland.
7. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. (2006)
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected
with tuberculosis and HIV in a rural area of South Africa. Lancet 368:
1575–1580.
8. Basu S, Friedland GH, Medlock J, Andrews JR, Shah NS, et al. (2009) Averting
epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci USA
106: 7672–7677.
9. Mitnick CD, Shin SS, Seung KJ, Rich ML, Atwood SS, et al. (2008)
Comprehensivetreatmentofextensivelydrug-resistanttuberculosis.NEnglJMed
359: 563–574.
10. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, et al. (2003) Community-based
therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348:
119–128.
11. Solari L, Acuna-Villaorduna C, Soto A, Agapito J, Perez F, et al. (2008) A
clinical prediction rule for pulmonary tuberculosis in emergency departments.
Int J Tuberc Lung Dis 12: 619–624.
12. Novelli EM, Hittner JB, Davenport GC, Ouma C, Were T, et al. (2010) Clinical
predictors of severe malarial anaemia in a holoendemic Plasmodium falciparum
transmission area. Br J Haematol 149: 711–721.
13. Costello C, Nelson KE, Jamieson DJ, Spacek L, Sennun S, et al. (2005)
Predictors of low CD4 count in resource-limited settings: based on an
antiretroviral-naive heterosexual thai population. J Acquir Immune Defic Syndr
39: 242–248.
14. Mwaniki MK, Nokes DJ, Ignas J, Munywoki P, Ngama M, et al. (2009)
Emergency triage assessment for hypoxaemia in neonates and young children in
a Kenyan hospital: an observational study. Bull World Health Organ 87:
263–270.
15. Vashakidze L, Salakaia A, Shubladze N, Cynamon M, Barbakadze K, et al.
(2009) Prevalence and risk factors for drug resistance among hospitalized
tuberculosis patients in Georgia. Int J Tuberc Lung Dis 13: 1148–1153.
16. Schreiber Y, Herrera A, Wilson D, Wallengren K, Draper R, et al. (2009)
Tuberculosis retreatment category predicts resistance in hospitalized retreatment
patients in a high HIV prevalence area. Int J Tuberc Lung Dis 13: 1274–1280.
17. Escombe AR, Moore DAJ, Gilman RH, Pan W, Navincopa M, et al. (2008) The
infectiousness of tuberculosis patients coinfected with HIV. PLoS Med 5: e188.
18. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, et al. (1989) A
prospective study of the risk of tuberculosis among intravenous drug users with
human immunodeficiency virus infection. N Engl J Med 320: 545–550.
19. Brust JCM, Gandhi NR, Carrara H, Osburn G, Padayatchi N (2010) High
treatment failure and default rates for patients with multidrug-resistant
tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung
Dis 14: 413–419.
20. Patel KB, Belmonte R, Crowe HM (1995) Drug malabsorption and resistant
tuberculosis in HIV-infected patients. N Engl J Med 332: 336–337.
21. South Africa Department of Health (2004) The South African National
Tuberculosis Control Programme Practical Guidelines.
22. Vittinghoff E, Glidden D, Shiboski S, McCulloch C (2004) Regression Methods
in Biostatistics. New York: Springer.
23. World Health Organization. (2010) Multidrug and Extensively Drug-Resistant
TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. Geneva:
World Health Organization.
Predictors of MDR & XDR TB in a High HIV Setting
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e1573524. Keshavjee S, Gelmanova I, Farmer P, Mishustin S, Strelis A, et al. (2008)
Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a
retrospective cohort study. Lancet 372: 1403–9.
25. Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, et al. (2008)
Exogenous reinfection as a cause of multidrug-resistant and extensively drug-
resistant tuberculosis in rural South Africa. J Infect Dis 198: 1582–1589.
26. Basu S, Andrews JR, Poolman EM, Gandhi NR, Shah NS, et al. (2007)
Prevention of nosocomial transmission of extensively drug-resistant tuberculosis
in rural South African district hospitals: an epidemiological modelling study.
Lancet 370: 1500–1507.
27. Churchyard GJ, Corbett EL, Kleinschmidt I, Mulder D, De Cock KM (2000)
Drug-resistant tuberculosis in South African gold miners: incidence and
associated factors. Int J Tuberc Lung Dis 4: 433–440.
28. Punnotok J, Shaffer N, Naiwatanakul T, Pumprueg U, Subhannachart P, et al.
(2000) Human immunodeficiency virus-related tuberculosis and primary drug
resistance in Bangkok, Thailand. Int J Tuberc Lung Dis 4: 537–543.
29. Campos PE, Suarez PG, Sanchez J, Zavala D, Arevalo J, et al. (2003) Multidrug-
resistant Mycobacterium tuberculosis in HIV-infected persons, Peru. Emerging
Infect. Dis 9: 1571–1578.
30. Gordin FM, Nelson ET, Matts JP, Cohn DL, Ernst J, et al. (1996) The impact of
human immunodeficiency virus infection on drug-resistant tuberculosis.
Am J Respir Crit Care Med 154: 1478–1483.
31. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, et al. (2001)
Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc
Lung Dis 5: 887–893.
32. Suchindran S, Brouwer ES, Van Rie A (2009) Is HIV infection a risk factor for
multi-drug resistant tuberculosis? A systematic review. PLoS ONE 4: e5561.
33. Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G (2007) Multidrug-
resistant and extensively drug-resistant tuberculosis: implications for the HIV
epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis
196(Suppl 3): S482–490.
34. Shenoi SV, Escombe AR, Friedland G (2010) Transmission of drug-susceptible
and drug-resistant tuberculosis and the critical importance of airborne infection
control in the era of HIV infection and highly active antiretroviral therapy
rollouts. Clin Infect Dis 50(Suppl 3): S231–237.
35. Kliiman K, Altraja A (2009) Predictors of extensively drug-resistant pulmonary
tuberculosis. Ann Intern Med 150: 766–775.
36. Cox HS, McDermid C, Azevedo V, Muller O, Coetzee D, et al. (2010)
Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high
HIV prevalence setting in Khayelitsha, South Africa. PLoS ONE 5: e13901.
37. Casal M, Vaquero M, Rinder H, Tortoli E, Grosset J, et al. (2005) A case-
control study for multidrug-resistant tuberculosis: risk factors in four European
countries. Microb Drug Resist 11: 62–67.
38. Drobniewski F, Balabanova Y, Nikolayevsky V, Ruddy M, Kuznetzov S, et al.
(2005) Drug-resistant tuberculosis, clinical virulence, and the dominance of the
Beijing strain family in Russia. JAMA 293: 2726–2731.
39. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE (2008) Impact
of enhanced tuberculosis diagnosis in South Africa: a mathematical model of
expanded culture and drug susceptibility testing. Proc Natl Acad Sci USA 105:
11293–11298.
Predictors of MDR & XDR TB in a High HIV Setting
PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e15735